Bath Savings Trust Co Sells 1,218 Shares of Johnson & Johnson $JNJ

Bath Savings Trust Co cut its position in Johnson & Johnson (NYSE:JNJ) by 3.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,027 shares of the company’s stock after selling 1,218 shares during the quarter. Bath Savings Trust Co’s holdings in Johnson & Johnson were worth $4,892,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Brighton Jones LLC raised its position in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares during the last quarter. Hudson Value Partners LLC raised its position in shares of Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock worth $5,648,000 after acquiring an additional 1,022 shares during the last quarter. Two Sigma Investments LP bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $9,222,000. First Heartland Consultants Inc. bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $1,269,000. Finally, 49 Wealth Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $211,000. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on JNJ shares. Royal Bank Of Canada raised their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Barclays lifted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Citigroup lifted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday, August 21st. Bank of America lifted their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Thursday, July 17th. Finally, Guggenheim reiterated a “neutral” rating and issued a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $177.87.

Johnson & Johnson Trading Down 1.7%

Shares of Johnson & Johnson stock opened at $174.25 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The stock has a 50 day moving average price of $172.42 and a two-hundred day moving average price of $161.62. The stock has a market capitalization of $419.66 billion, a PE ratio of 18.64, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter last year, the firm posted $2.82 earnings per share. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.